" class="no-js "lang="en-US"> Fujitsu Launches Solution Which Supports Cloud-based Epic EPRs - Medtech Alert
Friday, March 29, 2024

Fujitsu Launches Solution Which Supports Cloud-based Epic EPRs

Fujitsu has launched a solution which will allow NHS trusts and other healthcare organisations in the UK to host their Epic electronic patient record (EPR) in the cloud.

This means that for the first time, healthcare organisations looking to deploy Epic have the option to run the electronic patient record (EPR) in the cloud via Fujitsu’s Epic in the Cloud.

The solution is designed to help address challenges that NHS trusts and UK healthcare organisations can face in making the business case for Epic and then deploying and consuming upgrades for the EPR.

The infrastructure is evergreen, meaning Epic upgrades can be easily tested and deployed, removing the need for unplanned technology investments or regular infrastructure refreshes. Healthcare organisations can therefore focus their time and resources on accelerating their digital maturity and broader data strategies.

Matthew Chase, healthcare chief technology officer, Fujitsu UK, and former deputy chief technology officer at Guy’s and St Thomas’ NHS Foundation Trust, said: “Until now, trusts that wanted to run Epic had to create the infrastructure to host it on-premises or work with a third-party hosting service.

“Now, they have the option to have Fujitsu host it for them on AWS. That means trusts can look to get the resilience and flexibility of cloud computing, the benefits of Epic, and the support they need from Fujitsu and its partners to generate the cost savings and clinical benefits they expect, faster.”

Fujitsu in the UK has introduced Epic in the Cloud in support for the Amazon Web Services (AWS) for Health initiative which has been designed to make it easier for health professionals to select the right tools, partners and industry specialists to address their highest-priority workloads across the healthcare community. 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more